By all accounts the one piece missing from the puzzle for Jomed NV , the small European supplier making waves in the highly competitive field of interventional cardiology, has been a US presence. Having successfully established itself in Europe and fresh on the heels of a well-received IPO, Jomed officials have known for years that they would, eventually, have to meet the companies it competes against in Europe, companies such as Guidant Corp. , Boston Scientific Corp. , and the Avecor Cardiovascular Inc. subsidiary of Medtronic Inc. , on their home turf. (See "Jomed's Rising Star," IN VIVO, April 1999 [A#1999800093.)
Thus, most industry observers saw the value of Jomed's deal for EndoSonics Corp. not in the latter's interventional ultrasound...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?